PMID- 16007412
OWN - NLM
STAT- MEDLINE
DCOM- 20060203
LR  - 20181113
IS  - 0012-186X (Print)
IS  - 0012-186X (Linking)
VI  - 48
IP  - 9
DP  - 2005 Sep
TI  - Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress 
      and inflammation in type 2 diabetic patients.
PG  - 1919-24
AB  - AIM/HYPOTHESIS: Evidence suggests that postprandial hyperglycaemia may be a 
      cardiovascular risk factor in diabetes. Oxidative stress and inflammation are 
      involved in the pathogenesis of diabetic complications and previous studies have 
      shown increased oxidative stress and inflammation in the postprandial phase in 
      diabetic patients. The aim of the present study was to evaluate whether 
      controlling postprandial hyperglycaemia with S21403 (mitiglinide) is accompanied 
      by a reduced generation of oxidative stress and inflammation. SUBJECTS AND 
      METHODS: Forty type 2 diabetic patients participated in the study. Two different 
      breakfast-tests were performed in each patient, with placebo or S21403. Plasma 
      nitrotyrosine, plasma malondialdehyde (MDA), oxidised LDL (oxLDL), plasma total 
      radical-trapping antioxidant parameter (TRAP), IL-6, IL-18, TNF-alpha, plasma 
      glucose and insulin were measured. RESULTS: After the administration of S21403, 
      40 mg, a rapid stimulation of insulin secretion was observed, accompanied by a 
      reduction of postprandial hyperglycaemia. With S21403, a significant decrease of 
      either nitrotyrosine, MDA and oxLDL levels, and a preservation of plasma TRAP 
      compared with placebo was found. Significant decreases of IL-6, IL-18 and 
      TNF-alpha were also observed with S21403 compared with placebo. 
      CONCLUSIONS/INTERPRETATION: This study shows that controlling postprandial 
      hyperglycaemia with S21403 significantly improves the cluster of oxidative stress 
      and inflammation markers that are increased in the postprandial state in diabetic 
      patients.
FAU - Assaloni, R
AU  - Assaloni R
AD  - Department of Pathology and Medicine, Experimental and Clinical, University of 
      Udine, Udine, Italy.
FAU - Da Ros, R
AU  - Da Ros R
FAU - Quagliaro, L
AU  - Quagliaro L
FAU - Piconi, L
AU  - Piconi L
FAU - Maier, A
AU  - Maier A
FAU - Zuodar, G
AU  - Zuodar G
FAU - Motz, E
AU  - Motz E
FAU - Ceriello, A
AU  - Ceriello A
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050709
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
RN  - 0 (Antioxidants)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Indoles)
RN  - 0 (Interleukin-18)
RN  - 0 (Interleukin-6)
RN  - 0 (Isoindoles)
RN  - 0 (Placebos)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - D86I0XLB13 (mitiglinide)
SB  - IM
MH  - Antioxidants/metabolism
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Indoles/*therapeutic use/toxicity
MH  - Inflammation/prevention & control
MH  - Interleukin-18/blood
MH  - Interleukin-6/blood
MH  - Isoindoles
MH  - Oxidative Stress/*drug effects
MH  - Placebos
MH  - Postprandial Period
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2005/07/12 09:00
MHDA- 2006/02/04 09:00
CRDT- 2005/07/12 09:00
PHST- 2004/10/14 00:00 [received]
PHST- 2005/03/20 00:00 [accepted]
PHST- 2005/07/12 09:00 [pubmed]
PHST- 2006/02/04 09:00 [medline]
PHST- 2005/07/12 09:00 [entrez]
AID - 10.1007/s00125-005-1849-5 [doi]
PST - ppublish
SO  - Diabetologia. 2005 Sep;48(9):1919-24. doi: 10.1007/s00125-005-1849-5. Epub 2005 
      Jul 9.